Semaglutide and testosterone: The science of combining therapies for men

In men with obesity (BMI over 30) and symptoms of low testosterone, semaglutide may be paired with a hormone treatment chosen after LH and FSH testing. Those results show whether the problem lies in the testes (primary hypogonadism) or in the brain’s signaling to them (secondary or functional hypogonadism). That distinction decides whether testosterone replacement therapy (TRT) or a treatment that raises the body’s own production, such as Enclomiphene, is the better fit. The approach targets the overlap in which visceral fat can lower testosterone and low testosterone can make fat loss harder.

Key takeaways

• For men with obesity (BMI over 30) and confirmed hypogonadism, semaglutide may be combined with a hormone treatment chosen after LH and FSH testing. TRT suppresses sperm production and is the usual option when the testes are failing. Men with secondary or functional hypogonadism may be candidates for Enclomiphene, which raises the body’s own testosterone.
• Excess adipose tissue carries aromatase, the enzyme that converts testosterone to estradiol.^[1] Reducing fat mass with semaglutide may lower this conversion, but the hormone plan should follow LH, FSH, symptoms, and fertility goals rather than assume TRT is needed.
• Weight loss with semaglutide reduces lean mass along with fat mass, so resistance training and adequate protein remain central, with hormone treatment added only when hypogonadism is confirmed.
• Hypogonadism is diagnosed from persistent symptoms plus low testosterone, as the European Association of Urology guidelines describe (Salonia et al., 2021).^[2] LH and FSH then show whether the testes or the pituitary signaling is the problem, which shapes the treatment path.
• Testing should use a morning blood draw and include total testosterone, free testosterone, LH, and FSH, with other labs such as estradiol, a blood count, a metabolic panel, and PSA added according to age and history.

The relationship

The connection between obesity and hypogonadism, the clinical term for low testosterone, runs in both directions. A 2007 prospective cohort study of 1,667 Boston-area men aged 40 to 70, published in the Journal of Clinical Endocrinology and Metabolism (Travison et al.), found that a 4 to 5 kg/m² rise in body mass index was associated with a fall in total testosterone comparable to about 10 years of aging.^[3] Fat tissue contains aromatase, which converts testosterone to estradiol, and one proposed model describes a cycle in which low testosterone favors abdominal fat gain and the added fat lowers testosterone further.^[1]

Weight and hormones have often been treated separately. A man might receive testosterone replacement therapy (TRT) for energy and libido, or be told to manage his weight through diet and exercise. A 2010 review in Molecular and Cellular Endocrinology (Dixon) linked obesity to cardiovascular disease, type 2 diabetes, several cancers, osteoarthritis, and psychological problems, and concluded that weight loss appears to be the most effective therapy for obesity and its related conditions.^[4]

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) randomized 1,961 adults with overweight or obesity and no diabetes to once-weekly semaglutide 2.4 mg or placebo, both with a lifestyle intervention. After 68 weeks, body weight fell by 14.9% with semaglutide and by 2.4% with placebo plus lifestyle intervention alone.^[5] Some clinicians combine semaglutide with a hormone treatment selected after LH and FSH testing in carefully evaluated men, but direct long-term evidence for the combination is limited. Whatever hormone treatment is used, resistance training and adequate protein remain central for preserving lean mass.

How it works

Breaking the enzymatic feedback loop

Adipose tissue, or body fat, contains aromatase, an enzyme that converts testosterone into estradiol, an estrogen. In men with severe obesity, total and free testosterone tend to be lower and estradiol higher, and testosterone falls without the rise in LH and FSH that would normally compensate.^[1]

Semaglutide reduces fat mass, which may lower total aromatase activity and the conversion of testosterone to estradiol. This is a mechanistic expectation rather than an outcome measured in combination trials. In men with clinically low levels, any rebound from weight loss may be slow or incomplete, which is why LH and FSH are used to decide what kind of hormone treatment fits. In secondary or functional hypogonadism the testes are intact, so a treatment that raises LH can be an option. Enclomiphene blocks estrogen receptors in the hypothalamus, which raises LH and FSH and prompts the testes to make more testosterone. When the testes themselves are failing (high LH with low testosterone), raising LH does not help, and TRT is the standard option.

Preserving lean mass during caloric restriction

Rapid weight loss with drugs like semaglutide can reduce lean mass, also called fat-free mass, along with fat. The term sarcopenia should be reserved for cases with documented low strength or physical performance. Lean mass loss is one reason resistance training and adequate protein are emphasized during treatment.

Testosterone is anabolic, meaning it supports protein synthesis and muscle growth. In men with confirmed hypogonadism, some clinicians pair semaglutide with hormone treatment to help direct weight loss toward fat while better protecting muscle, although this rationale has not been tested in long-term combination trials. Skeletal muscle is a major contributor to resting metabolic rate and long-term physical function.

Appetite, motivation, and diagnosis

The two treatments act on the brain in different ways. Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that acts on appetite centers, including the hypothalamus, to increase satiety. Testosterone acts on receptors in the brain that influence mood, motivation, and sex drive.

Men with low testosterone often report fatigue and low motivation, which can make regular exercise harder. Treating confirmed hypogonadism may improve energy and make consistent physical activity easier to sustain.

The European Association of Urology 2021 guidelines (Salonia et al.) describe late-onset hypogonadism as a clinical condition that combines low circulating testosterone with specific symptoms.^[2] According to the 2018 American Urological Association guideline, low testosterone should be confirmed with two early-morning total testosterone measurements taken on separate occasions, with 300 ng/dL as a reasonable cut-off, and LH should be measured in men with low testosterone.^[6] Free testosterone adds information when total testosterone is borderline or SHBG may be abnormal, and equilibrium dialysis is the reference method for measuring it directly. Samples are ideally drawn between 07:00 and 11:00. LH and FSH then show whether the cause is primary or secondary, which shapes the treatment path.

Conditions linked to it

The combination of semaglutide and a hormone treatment chosen after LH and FSH testing is mainly considered in men who sit at the intersection of obesity, insulin resistance, and low testosterone, a risk cluster often described as metabolic syndrome. Metabolic syndrome is commonly defined (for example, under the NCEP ATP III criteria) by at least three of five findings: central (abdominal) obesity, elevated triglycerides, low HDL cholesterol, elevated blood pressure, and elevated fasting glucose. Type 2 diabetes can be related, but it is not required for the diagnosis.

Hypogonadal obesity
This term describes men caught in the cycle of low testosterone and excess visceral fat. It is not simply a matter of overeating: in the proposed model, the low testosterone state itself favors abdominal fat storage.^[1]

Type 2 diabetes and insulin resistance
A 2011 meta-analysis of 37 studies in the International Journal of Andrology (Corona et al.) found that men with type 2 diabetes had lower testosterone than men without it, even after adjustment for age and BMI, and that men who later developed diabetes had lower baseline total testosterone.^[7] Pooling the few randomized trials available, the same analysis found that testosterone therapy in men with type 2 diabetes was associated with lower fasting glucose, HbA1c, fat mass, and triglycerides.^[7] Testosterone therapy is not a treatment for diabetes itself. Semaglutide is FDA-approved to treat type 2 diabetes.

Cardiovascular disease risk
Both obesity and low testosterone are linked to adverse cardiovascular outcomes, and testosterone therapy has been controversial regarding heart health. The TRAVERSE trial (Lincoff et al., New England Journal of Medicine, 2023) randomized 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease to daily testosterone gel or placebo. Over a mean follow-up of 33 months, major adverse cardiac events occurred in 7.0% of the testosterone group and 7.3% of the placebo group, meeting the criterion for noninferiority; atrial fibrillation, acute kidney injury, and pulmonary embolism were more common with testosterone.^[8] In STEP 1, semaglutide also improved cardiometabolic risk factors more than placebo.^[5]

Each drug has been studied on its own, but long-term studies of semaglutide combined with Enclomiphene or testosterone therapy are lacking, so current practice extrapolates from single-drug trials and smaller studies.

Symptoms and signals

The combined weight and hormone approach generally applies to men who have signs of both metabolic dysfunction and hormonal deficiency.

It helps to separate overlapping symptoms. Obesity-related symptoms often include snoring or sleep apnea, reflux, joint pain, and shortness of breath with exertion. Hypogonadism is more likely to show up as reduced libido, fewer morning erections, low energy, depressed mood, and loss of strength or muscle despite similar training. Because these can overlap, and because sleep apnea, medications, and illness can lower testosterone, it is reasonable to seek a formal evaluation if symptoms persist for several months, particularly with central obesity or worsening metabolic labs.

• Central adiposity: You carry most of your weight in the belly, a firm “beer gut” even if you don’t drink heavily.
• Muscle weakness: You feel weaker in the gym, or your limbs look thinner while your midsection grows.
• Persistent fatigue: You feel tired even after a full night’s sleep, often with a slump in the mid-afternoon.
• Low libido: A noticeable drop in sexual desire or in the quality of morning erections.
• Diet plateau: You have tried caloric restriction but your weight barely moves, or you regain it quickly.
• Brain fog: Difficulty concentrating or feeling sharp at work.

What to do about it

If these symptoms sound familiar, the next step is a medical evaluation rather than self-treatment.

Decision-making should be individualized. A clinician should confirm hypogonadism with appropriately timed morning testing, review contributing factors (sleep, alcohol, opioids or other medications, pituitary disease), and discuss goals such as energy, sexual function, cardiometabolic risk reduction, and physical performance. If you are trying to conceive, discuss options first: TRT suppresses sperm production, and the 2018 American Urological Association guideline states that testosterone therapy should not be prescribed to men who want to preserve fertility.^[6]

Monitoring matters as much as starting therapy. Follow-up labs are usually checked within the first months after starting or changing treatment, then at regular intervals once stable, with sooner checks if symptoms, side effects, or abnormal results appear. For men on TRT, a rise in hematocrit is the most common adverse effect and is checked routinely.

1. Blood panel
Testing should be done in the morning, ideally between 07:00 and 11:00, and repeated for confirmation when appropriate. The core tests are total testosterone, free testosterone, LH, and FSH; free testosterone measured directly by equilibrium dialysis with LC-MS/MS avoids estimates that depend on SHBG. Estradiol, a complete blood count, a Comprehensive Metabolic Panel, and PSA for men 40 and older are commonly added, with prolactin, thyroid tests, and lipids when clinically indicated. Symptoms plus low morning testosterone support the diagnosis, and LH and FSH are needed to classify the cause before choosing treatment. A separate low testosterone testing guide covers what to order and how to read results.

2. Sequencing treatment
If you qualify for both treatments, some clinicians stagger start dates so side effects are easier to attribute. The hormone treatment is chosen from the LH and FSH results, and semaglutide is usually started at a low dose (0.25 mg weekly) and increased gradually. Nausea that appears after semaglutide starts is more likely due to semaglutide, since nausea and diarrhea were its most common adverse events in STEP 1.^[5]

3. Monitor and reassess
Some men plan to use GLP-1 therapy for a defined period, while others plan for longer-term treatment. Stopping it commonly leads to weight regain. In the STEP 4 randomized clinical trial (Rubino et al., JAMA, 2021), 803 adults who had lost an average of 10.6% of body weight during a 20-week semaglutide run-in were randomized to continue semaglutide or switch to placebo. Over the next 48 weeks, weight fell a further 7.9% with continued treatment and rose 6.9% after the switch to placebo.^[9] If a taper is considered, it should rest on sustained weight stability, improved metabolic markers, and a durable lifestyle plan, with close follow-up to catch early regain.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, by licensed providers. In Veedma’s protocol, Enclomiphene is the first treatment for secondary or functional hypogonadism, prescribed alone or as the Enclomiphene plus tadalafil tablet when appropriate. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

Myth vs fact

Myth: Taking testosterone will make me lose weight automatically without dieting.

Fact: In men with hypogonadism, testosterone therapy can improve body composition, with more muscle and less fat, but it rarely causes large scale-weight loss without caloric control.

Myth: Semaglutide melts muscle, so I shouldn’t take it.

Fact: All weight loss involves some lean mass loss. Combining semaglutide with resistance training, adequate protein intake, and treatment of confirmed hypogonadism when indicated can help reduce it.

Myth: This combination is illegal or dangerous “doping.”

Fact: When prescribed for diagnosed obesity and hypogonadism, this is legitimate medical therapy. Using these drugs without a medical indication to gain a competitive edge in sport is what counts as doping.

Myth: I can just take pills from the internet.

Fact: Counterfeit semaglutide and testosterone from unregulated labs are sold online and may contain the wrong dose or contaminants. Use a licensed pharmacy with a valid prescription.

Bottom line

Combining semaglutide with a hormone treatment selected after LH and FSH testing is an individualized approach for men who have both obesity and hypogonadism. Semaglutide helps create the caloric deficit needed for weight loss, while treating the hormonal disorder may support energy, sexual function, and preservation of fat-free mass. LH and FSH determine whether a treatment that restores the body’s own production, such as Enclomiphene, or TRT is the better fit. Direct long-term evidence for the combination remains limited, so accurate blood work, medical monitoring, resistance training, adequate protein, and lasting lifestyle change remain essential.

References

1. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt–a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52:49-51. PMID: 10342671
2. Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. Eur Urol. 2021;80:333-357. PMID: 34183196
3. Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92:549-55. PMID: 17148559
4. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. 2010;316:104-8. PMID: 19628019
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. PMID: 33567185
6. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
7. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34:528-40. PMID: 20969599
8. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
9. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325:1414-1425. PMID: 33755728